Table 3.
(A) Median of overall survival analysis in all metastatic and non-metastatic gastric cancer patients in the whole study. (B) Death percentage analysis in all metastatic and non-metastatic gastric cancer patients in the whole study
| Group | Metastatic | Non-metastatic | ||
|---|---|---|---|---|
| Total number | BCc1 (n = 33) | Placebo (n = 30) | BCc1 (n = 30) | Placebo (n = 30) |
| (A) Median of overall survival analysis | ||||
| Median (days) | 174 | 62 | 529 | 345 |
| Std. error | 46.748 | 46.643 | 69.263 | 107.218 |
| Median 95% CI (lower) | 82.374 | 0.000 | 393.245 | 134.854 |
| Median 95% CI (upper) | 265.626 | 153.421 | 664.755 | 555.146 |
| P-value for test of equality of survival distributions | 0.04 | 0.05 | ||
| HR (BCc1/Placebo) |
0.5 | 0.324 | ||
| (B) Death percentage analysis | ||||
| Death percentage | 48.5% | 63.3% | 12.9% | 29.6% |
Test of equality of survival distributions (for Bcc1 and placebo groups) assay with Log Rank (Mantel-Cox)